Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.34 |
| ▸ | KDM4A | O75164 | 2/20 | 0.34 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1508314 | 1.00 | EPHX1 (0.50) | EPHX1LMNAKISS1RSIGMAR1HTR2A | |
| SCHEMBL2042220 | 1.00 | EPHX1 (0.50) | EPHX1LMNAKISS1RSIGMAR1HTR2A | |
| SCHEMBL15346172 | 1.00 | EPHX1 (0.50) | EPHX1LMNAKISS1RSIGMAR1HTR2A | |
| SCHEMBL17104335 | 1.00 | EPHX1 (0.50) | EPHX1LMNAKISS1RSIGMAR1HTR2A | |
| SCHEMBL17104333 | 1.00 | EPHX1 (0.50) | EPHX1LMNAKISS1RSIGMAR1HTR2A | |
| SCHEMBL25122641 | 1.00 | EPHX1 (0.50) | EPHX1LMNAKISS1RSIGMAR1HTR2A | |
| SCHEMBL17104337 | 1.00 | EPHX1 (0.50) | EPHX1LMNAKISS1RSIGMAR1HTR2A | |
| SCHEMBL11213990 | 1.00 | EPHX1 (0.50) | EPHX1LMNAKISS1RSIGMAR1HTR2A | |
| SCHEMBL22564692 | 1.00 | EPHX1 (0.50) | EPHX1LMNAKISS1RSIGMAR1HTR2A | |
| SCHEMBL28266891 | 1.00 | EPHX1 (0.50) | EPHX1LMNAKISS1RSIGMAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| EP-2421874-B1 | COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF | EVONIK DEGUSSA GMBH (DE) | 2015-09-30 | — | — | EP | claimed |
| WO-2024097775-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| CN-107209146-B | Electrochemical gas sensor and electrolyte for electrochemical gas sensor | 德尔格安全股份两合公司 | 2024-03-12 | — | — | CN | disclosed |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230357133-A1 | NANOMATERIALS COMPRISING CARBONATES | BEAM THERAPEUTICS INC. | 2023-11-09 | — | — | US | disclosed |
| WO-2023134465-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2023-07-20 | — | — | WO | disclosed |
| US-11702402-B2 | Small molecules that block proteasome-associated ubiquitin receptor RPN13 function and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| WO-2023109944-A1 | TLR MODULATOR AND USE THEREOF | 映恩生物制药（苏州）有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-11312964-B2 | Compositions and methods for modulating growth hormone receptor expression | IONIS PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20170239397-A1 | MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS | UNITED STATES GOVERNMENT | 2017-08-24 | — | — | US | disclosed |
| US-9644195-B2 | Compounds and methods for purification of serine proteases | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| WO-2012174479-A1 | IN VIVO PROTEOMICS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-12-20 | — | — | WO | disclosed |
| US-20120149630-A1 | END-MODIFIED POLY(BETA-AMINO ESTERS) AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-06-14 | — | — | US | disclosed |
| US-20080242626-A1 | End-Modified Poly(beta-amino esters) and Uses Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-10-02 | — | — | US | disclosed |
| US-20070043095-A1 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | IPSEN PHARMA S.A.S. (FR) | 2007-02-22 | — | — | US | disclosed |
| EP-0031924-B1 | USE OF ALCANOL-AMINE SALTS OF CYCLIC AMIDOCARBOXYLIC ACIDS AS CORROSION INHIBITORS IN AQUEOUS SYSTEMS | BASF Aktiengesellschaft (DE) | 1983-05-18 | — | — | EP | disclosed |
| EP-0031924-A1 | Use of alcanol-amine salts of cyclic amidocarboxylic acids as corrosion inhibitors in aqueous systems | BASF Aktiengesellschaft (DE) | 1981-07-15 | — | — | EP | disclosed |
| US-4190601-A | Production of tertiary amines by reductive alkylation | UNION CARBIDE CORPORATION (US) | 1980-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149630-A1 | END-MODIFIED POLY(BETA-AMINO ESTERS) AND USES THEREOF | PARN, PARG, POLL | EPHX1 4180/4885LMNA 566/4885KISS1R 2381/4885 |
| US-20080242626-A1 | End-Modified Poly(beta-amino esters) and Uses Thereof | PARN, PARG, POLL | EPHX1 4180/4885LMNA 566/4885KISS1R 2381/4885 |
| US-20170239397-A1 | MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS | ALG1, FIBP, COL2A1 | EPHX1 3857/4885LMNA 3162/4885KISS1R 4272/4885 |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | EPHX1 4120/4885LMNA 2220/4885KISS1R 1022/4885 |
| US-20230357133-A1 | NANOMATERIALS COMPRISING CARBONATES | PHOSPHO1, CA13, SGMS2 | EPHX1 2426/4885LMNA 211/4885KISS1R 4769/4885 |
| US-20070043095-A1 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | SSTR2, SSTR5, SSTR3 | EPHX1 3976/4885LMNA 4079/4885KISS1R 185/4885 |
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | EPHX1 1684/4885LMNA 1656/4885KISS1R 2435/4885 |
| US-11702402-B2 | Small molecules that block proteasome-associated ubiquitin receptor RPN13 function and uses thereof | CRBN, PSME3, PSMB10 | EPHX1 4324/4885LMNA 2542/4885KISS1R 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.